SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced United States Federal Trade Commission and Department of Justice clearance under provisions of the Hart-Scott-Rodino Antitrust Improvements Act for the previously announced global collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for PEG-Interferon lambda. The collaboration agreement became effective upon clearance, and ZymoGenetics will receive payment of an $85.0 million licensing fee.
